DE69714023T2 - Cyclopentane heptan(ene)säure, 2-heteroarylalkenylderivate als therapeutisches mittel - Google Patents

Cyclopentane heptan(ene)säure, 2-heteroarylalkenylderivate als therapeutisches mittel

Info

Publication number
DE69714023T2
DE69714023T2 DE69714023T DE69714023T DE69714023T2 DE 69714023 T2 DE69714023 T2 DE 69714023T2 DE 69714023 T DE69714023 T DE 69714023T DE 69714023 T DE69714023 T DE 69714023T DE 69714023 T2 DE69714023 T2 DE 69714023T2
Authority
DE
Germany
Prior art keywords
derivatives
acid
compounds
substituted
ene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69714023T
Other languages
English (en)
Other versions
DE69714023D1 (en
Inventor
M Burk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Application granted granted Critical
Publication of DE69714023D1 publication Critical patent/DE69714023D1/de
Publication of DE69714023T2 publication Critical patent/DE69714023T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Fats And Perfumes (AREA)
DE69714023T 1996-02-29 1997-02-20 Cyclopentane heptan(ene)säure, 2-heteroarylalkenylderivate als therapeutisches mittel Expired - Fee Related DE69714023T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/608,794 US5741810A (en) 1996-02-29 1996-02-29 Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
PCT/US1997/002313 WO1997031895A2 (en) 1996-02-29 1997-02-20 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

Publications (2)

Publication Number Publication Date
DE69714023D1 DE69714023D1 (en) 2002-08-22
DE69714023T2 true DE69714023T2 (de) 2003-03-13

Family

ID=24438034

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69714023T Expired - Fee Related DE69714023T2 (de) 1996-02-29 1997-02-20 Cyclopentane heptan(ene)säure, 2-heteroarylalkenylderivate als therapeutisches mittel

Country Status (13)

Country Link
US (4) US5741810A (de)
EP (1) EP0888298B1 (de)
JP (1) JP4226650B2 (de)
KR (1) KR19990087352A (de)
CN (1) CN1133434C (de)
AT (1) ATE220664T1 (de)
AU (1) AU725145B2 (de)
BR (1) BR9707892A (de)
CA (1) CA2247208A1 (de)
DE (1) DE69714023T2 (de)
ES (1) ES2178756T3 (de)
HK (1) HK1017671A1 (de)
WO (1) WO1997031895A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US6169111B1 (en) * 1995-06-07 2001-01-02 Alcon Laboratories, Inc. Conformationally rigid aryl prostaglandins for use in glaucoma therapy
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
TR200000671T2 (tr) * 1997-09-09 2000-07-21 The Procter & Gamble Company FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler.
DE69832513T2 (de) * 1997-09-09 2006-07-13 Duke University Aromatische c16-c20-substituierte tetrahydro-prostaglandinen verwendbar wie fp agoniste
DE69809268T2 (de) * 1997-09-09 2003-08-28 Procter & Gamble Aromatische c16-c20-substituierte tetrahydro-prostaglandine und ihre verwendung als prostaglandin f agonisten
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
MXPA01008955A (es) 1999-03-05 2002-04-24 Procter & Gamble Analogos de prostaglandinas selectivas de fp no saturadas de c16.
AU3385900A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
US6826874B2 (en) * 1999-06-30 2004-12-07 Nippon Steel Corporation Buckling restrained braces and damping steel structures
JP4000505B2 (ja) 1999-12-01 2007-10-31 第一三共株式会社 緑内障を治療するための併用剤
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US6248783B1 (en) * 2000-09-20 2001-06-19 Allergan Sales, Inc. Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
US6476064B1 (en) * 2001-06-13 2002-11-05 Allergan, Inc. Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
BR0202157A (pt) * 2002-06-07 2005-04-12 Univ Minas Gerais Peptìdeo obtido de veneno escorpião para uso como agente hipotensivo
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
JP2005511607A (ja) * 2003-07-10 2005-04-28 アラーガン、インコーポレイテッド ＥＰ２受容体作動剤としてのω−シクロアルキル１７−ヘテロアリールプロスタグランジンＥ２類似体
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
US7906552B2 (en) 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7101904B2 (en) * 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
ES2452026T3 (es) 2005-11-03 2014-03-31 Allergan, Inc. Prostaglandinas y análogos como agentes para disminuir la presión intraocular
CN101379051B (zh) 2006-02-07 2014-05-28 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
KR20170095402A (ko) 2009-11-09 2017-08-22 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US8783923B2 (en) * 2010-03-18 2014-07-22 Chung Yuan Christian University Auto lamp structure
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
CN109568672B (zh) 2013-03-15 2022-06-24 阿勒根公司 含有前列腺胺的眼内植入物
CA2908645A1 (en) 2013-04-01 2014-10-09 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
EP3351239B1 (de) 2013-10-31 2020-04-01 Allergan, Inc. Prostamidhaltige intraokularimplantate und verfahren zur verwendung davon
KR102159427B1 (ko) 2015-04-30 2020-09-24 알러간, 인코포레이티드 지방 감소를 위한 미용적 방법 및 치료적 용도
JP2023535399A (ja) 2020-07-21 2023-08-17 アラーガン、インコーポレイテッド プロスタミドが高充填された眼内インプラント

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845115A (en) * 1971-05-04 1974-10-29 Upjohn Co 15-lower alkoxy pgf compounds
US3781325A (en) * 1971-05-04 1973-12-25 Upjohn Co 15-methoxy-pgf2a
BE786251A (fr) * 1971-07-14 1973-01-15 Ici Ltd Nouveaux derives du cyclopentane
US3956284A (en) * 1972-07-13 1976-05-11 Pfizer Inc. Heterocyclic 15-substituted-ω-pentanorprostoglandins
US3980642A (en) * 1972-07-13 1976-09-14 Pfizer Inc. 15-Substitute D-ω-pentanorprostaglandins
DE2353159A1 (de) * 1972-07-13 1975-03-13 Pfizer Ketophosphonate und verfahren zu deren herstellung
US3974213A (en) * 1972-07-13 1976-08-10 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins
US4143051A (en) * 1972-07-13 1979-03-06 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
US4102894A (en) * 1975-11-19 1978-07-25 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
US3984424A (en) * 1972-11-08 1976-10-05 Pfizer Inc. P-biphenyl esters of 15-substituted-ω-pentanorprostaglandins
US4036832A (en) * 1974-07-03 1977-07-19 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
IT1053781B (it) * 1974-09-25 1981-10-10 Erba C S P A Ora Farmitalia Omega nor cicloalcil 13.14 deidro prostaglandine
IT1088966B (it) * 1977-11-15 1985-06-10 Erba Carlo Spa 13,14-dideidro-prostaglandine
DE3125271A1 (de) * 1981-06-24 1983-01-13 Schering Ag, 1000 Berlin Und 4619 Bergkamen (delta)(pfeil hoch)8(pfeil hoch),(pfeil hoch)9(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB8329559D0 (en) * 1983-11-04 1983-12-07 Erba Farmitalia Furyl derivatives of 16-substituted prostaglandins preparations
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
WO1996036599A1 (en) * 1995-05-18 1996-11-21 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents

Also Published As

Publication number Publication date
ES2178756T3 (es) 2003-01-01
US6680337B2 (en) 2004-01-20
EP0888298A2 (de) 1999-01-07
US6573390B2 (en) 2003-06-03
JP4226650B2 (ja) 2009-02-18
BR9707892A (pt) 1999-07-27
EP0888298B1 (de) 2002-07-17
US6096902A (en) 2000-08-01
WO1997031895A2 (en) 1997-09-04
ATE220664T1 (de) 2002-08-15
CA2247208A1 (en) 1997-09-04
AU725145B2 (en) 2000-10-05
US20030191178A1 (en) 2003-10-09
WO1997031895A3 (en) 1997-12-18
HK1017671A1 (en) 1999-11-26
KR19990087352A (ko) 1999-12-27
CN1218400A (zh) 1999-06-02
US5741810A (en) 1998-04-21
AU1958597A (en) 1997-09-16
CN1133434C (zh) 2004-01-07
US20010029304A1 (en) 2001-10-11
JP2000506139A (ja) 2000-05-23
DE69714023D1 (en) 2002-08-22

Similar Documents

Publication Publication Date Title
ATE220664T1 (de) Cyclopentane heptan(ene)säure, 2- heteroarylalkenylderivate als therapeutisches mittel
PT1137409E (pt) Composicoes e metodos para melhoramento da disfuncao sexual feminina humana
BR0112160A (pt) Agentes antiinflamatórios seletivos para glicocorticóides
CL2010000383A1 (es) Esteres y amida de acidos carboxilicos que contienen un agente anti-inflamatorio no esteroidal; composicion farmaceutica: y su uso como inhibidores de 5-lipoxigenasa para prevenir o aliviar edema de tejidos, inflamacion y congestion de la conjuntiva, de la nubosidad de la cornea y daños a tejidos oftalmicos (divisional sol. 3109-99).
DK0660716T3 (da) Ikke-sure 2-cycloalkyl- eller 2-arylkylderivater af cyclopentan-heptansyre som terapeutiske midler
NZ337769A (en) Methods and compositions for modulating responsiveness to corticosteroids
WO2001068138A3 (en) Intradermal-penetration agents for topical local anesthetic administration
CA2242991A1 (en) Use of antioxidant agents to treat cholestatic liver disease
WO1998022141A3 (en) Enhanced effects for hapten conjugated therapeutics
BR9811099A (pt) Inibidores de urocinase
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
AR000271A1 (es) Composiciones cosméticas par uso tópico utilizables para el bronceado y/o el tostado artificiales dela piel
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
NO993096L (no) Orale cyklosporinformuleringer
ZA967880B (en) Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha
AU1438699A (en) Fatty acid uninterrupted by a methylene as anti-inflammatory agents in superficial tissues of mammals
CO5271717A1 (es) Combinaciones farmaceuticas
WO2001001974A3 (en) Naaladase inhibitors in anxiety and memory disorders
BR9907655A (pt) Derivados de ácido di-hidróxi-hexanóico
DK1091733T3 (da) (-)-Pseudoephedrin som et sympatomimetisk lægemiddel
BR9712283A (pt) Método para inibir as cinases de proteìnas ativadas por tensão
DOP2002000356A (es) Conjugados de pregabalina lactosa
CA2251132A1 (en) Use of phosphinyloxyalkyl and phosphonamidoalkyl derivatives of cyclopentane(ene) as therapeutic agents
BG102342A (en) Optical active derivative of phenylpyrimidine as an anlgesics
YU58601A (sh) Derivati fenilalaninola

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee